The City of Hope Alpha Clinic: A roadmap for equitable and inclusive access to regenerative medicine therapies for all Californians

  • Post author:
  • Post category:

City of Hope has long developed groundbreaking therapies, and building on that success we want to democratize cancer care by bringing therapies to patients rather than making them come to…

Continue ReadingThe City of Hope Alpha Clinic: A roadmap for equitable and inclusive access to regenerative medicine therapies for all Californians

A comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California

  • Post author:
  • Post category:

We aim to markedly expand access of all Californians to outstanding cell and gene therapy trials for multiple conditions with unmet treatment needs. We will also contribute with excellence to…

Continue ReadingA comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California

A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus

  • Post author:
  • Post category:

Therapeutic Candidate or Device iPSC-derived CD19 CAR T cell therapy Indication Systemic Lupus Erythematosus Therapeutic Mechanism Depletion of CD19+ B cells and plasmablasts Unmet Medical Need Potential for drug-free remission…

Continue ReadingA Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus

Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

  • Post author:
  • Post category:

Therapeutic Candidate or Device SENTI-202 is an allogeneic off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cellular therapy targeting CD33 and/or FLT3 malignancies. Indication CD33 and/or FLT3 expressing hematologic malignancies,…

Continue ReadingSelective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis

  • Post author:
  • Post category:

Therapeutic Candidate or Device NXC-201 Indication AL Amyloidosis Therapeutic Mechanism Genetically modified T-cell targeting B-cell maturation antigen (BCMA) Unmet Medical Need Amyloid light-chain (AL) amyloidosis is a devastating, rare plasma…

Continue ReadingAutologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis